GlassScriptPhysician profile
Vinay Kumar Kotturi
NPI 1275030348
$1,654.80
in general payments reported to CMS, 2019-2025
21 companies · $969 in 2025
The $969 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $197 · 2024: $489 · 2025: $969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,654.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $340.11 | 2023-2025 | |
| Novo Nordisk INC | $286.28 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $208.24 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $104.55 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Grifols USA, LLC | $88.81 | 2025 | Prolastin-C Liquid |
| Pfizer INC. | $79.45 | 2024-2025 | |
| Exact Sciences Corporation | $77.16 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $70.46 | 2025 | |
| Axsome Therapeutics, INC. | $67.41 | 2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.19 | 2024-2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.47 | 2025 | Caplyta |
| Lundbeck LLC | $38.35 | 2025 | Rexulti |
| Abbott Laboratories | $38.19 | 2024-2025 | Freestyle Libre 3, Proclaim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.80 | 2024 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $29.27 | 2025 | Zoryve |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $21.51 | 2025 | Ponvory |
| Eisai INC. | $19.91 | 2024 | |
| Dynavax Technologies Corporation | $18.52 | 2025 | Heplisav-B |
| Takeda Pharmaceuticals U.S.A., INC. | $16.41 | 2025 | Trintellix |
| Amgen INC. | $13.99 | 2025 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $13.72 | 2023 | Verquvo, Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinay Kumar Kotturi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.